Joshua S. Boger, Director, 10% Owner at CervoMed Inc. (CRVO), bought 955,414 shares at $3.14 ($3.0M) on 2026-06-11, disclosed to the SEC on 2026-06-15.
Director Joshua S. Boger executed the largest insider purchase in CRVO's history by buying 955,414 shares at $3.14. This substantial bet by a 10% owner implies confidence in the stock's recovery despite a 40% year-to-date decline.
CRVO trades at $4.25, down 40.31% over the past year and 67.63% below its 52-week high of $13.13, though it remains 18.72% above the 52-week low of $3.58.
The $10.5 million private placement financing announced on June 10, 2026, provides capital for operations. Additionally, the company reported advancements in its neflamapimod program for Dementia Lewy Bodies (DLB) on March 17, 2026. Finally, the record-breaking insider purchase of 955,414 shares on June 11, 2026, serves as a bullish signal.
The stock exhibits extreme volatility with a beta of -4.54. Furthermore, recent news indicates insiders previously bought shares at an average price of $7.98, while the current price of $2.45 suggests the stock remains significantly below their entry point.
Something here stands out, but not much.
| Filing → |
| VRTX | SELL | 2017-01-03 | $483K | — | Filing → |
| VRTX | SELL | 2016-12-22 | $482K | — | Filing → |
| VRTX | SELL | 2016-12-16 | $504K | — | Filing → |